News Related to GVHD

Off-the-Shelf CAR-T Therapy CB-011 Shows High Response Rates in Multiple Myeloma; Broader CAR-T Advances Presented at 2026 Tandem Meetings

Jun 09, 2026

Updated data from the phase I CaMMouflage trial showed CB-011, the first allogeneic anti-BCMA CAR-T therapy with immune cloaking, achieved an approximately 92% overall response rate in relapsed/refractory multiple myeloma. The 2026 Tandem Meetings also highlighted advances in EB-103, KITE-753, and LV20.19 CAR-T constructs across lymphoma and CLL. Separately, NXC-201 reported a 95% complete response rate in AL amyloidosis.

Novel GVHD Prevention Regimen Shows Strong Results Without Standard Immunosuppressants

Mar 25, 2026

Interim results from the ABC phase 1/2b trial show a calcineurin inhibitor-free GVHD prevention regimen combining posttransplant cyclophosphamide, bortezomib, and abatacept achieved low GVHD rates and favorable survival outcomes. The approach enables earlier introduction of posttransplant maintenance therapies while reducing toxicity associated with conventional immunosuppressants.

AI Tool Predicts Life-Threatening Transplant Complications Months Before Symptoms Appear

Feb 17, 2026

Researchers developed BIOPREVENT, an AI-based tool that predicts chronic graft-versus-host disease and transplant-related mortality in stem cell and bone marrow transplant patients by analyzing blood biomarkers and clinical data collected 90-100 days post-transplant.

CAR-T Therapy Advances and Nanoparticle Immunotherapy Show Promise in Cancer Treatment

Feb 15, 2026

CAR-T cell therapy engineering advances at Tandem 2026 focus on reducing toxicity and improving access, while McGill researchers develop targeted nanoparticle immunotherapy for lymph node metastases with fewer side effects.